Darolutamide in Japanese patients with metastatic hormone‐sensitive prostate cancer: Phase 3 <scp>ARASENS</scp> subgroup analysis
In conclusion, efficacy outcomes showed positive trends for darolutamide plus ADT and docetaxel in Japanese patients with mHSPC, consistent with the overall population, despite higher risk factors. The combination was well tolerated, with no new safety signals in Japanese patients.
Authors
- Hiroaki Kikukawa
- Cora Nanette Sternberg (ORCID: https://orcid.org/0000-0003-3938-2627)
- Karim S. Fizazi (ORCID: https://orcid.org/0000-0002-6068-9474)
- Haruka Kakiuchi
- Matthew Smith (ORCID: https://orcid.org/0000-0002-1067-4821)
- Bertrand Tombal (ORCID: https://orcid.org/0000-0002-0093-8408)
- E. David Crawford (ORCID: https://orcid.org/0000-0002-5009-1655)
- Atsushi Mizokami (ORCID: https://orcid.org/0000-0002-5643-2182)
- Masanao Akiyama
- Iris Kuss
- Satoshi Fukasawa (ORCID: https://orcid.org/0000-0002-4759-4999)
- Hisashi Matsushima
- Takeo Kosaka
- Hiroji Uemura (ORCID: https://orcid.org/0000-0001-7943-1564)
- Masashi Kato (ORCID: https://orcid.org/0000-0002-8951-3640)
- Heikki Joensuu (ORCID: https://orcid.org/0000-0003-0281-2507)
- Rui Li (ORCID: https://orcid.org/0000-0001-7857-9735)
- Motohide Uemura (ORCID: https://orcid.org/0000-0001-7263-7965)
- Yasuhiro Hashimoto (ORCID: https://orcid.org/0000-0001-9240-9150)
- Motonobu Nakamura (ORCID: https://orcid.org/0000-0003-3038-1361)
- Maha Hussain
- Fred Saad
- Hiroyoshi Suzuki (ORCID: https://orcid.org/0000-0001-5838-114X)
Institutions
- Northwestern University (US)
- Toho University (JP)
- Cliniques Universitaires Saint-Luc (BE)
- NewYork–Presbyterian Hospital (US)
- Harvard University (US)
- Bayer (United States) (US)
- Cornell University (US)
- Université Paris-Saclay (FR)
- New York Hospital Queens (US)
- Institut Gustave Roussy (FR)
- Yokohama City University Medical Center (JP)
- University of California San Diego (US)
- Massachusetts General Hospital (US)
- Nagoya University Hospital (JP)
- National Hospital Organization Kyushu Cancer Center (JP)
- Presbyterian Hospital (US)
- Kanazawa University Hospital (JP)
- Keio University Hospital (JP)
- Chiba Cancer Center (JP)
- Toho University Medical Center Sakura Hospital (JP)
- Osaka University Hospital (JP)
- Tokyo Metropolitan Police Hospital (JP)
- Bayer (Japan) (JP)
- Hirosaki University Hospital (JP)
- Kumamoto Medical Center (JP)
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University
- Bayer (Germany) (DE)
- Université de Montréal (CA)
- Orion Corporation (United Kingdom) (GB)
- Yokohama City University (JP)
- UCLouvain (BE)
Publication Details
- Journal
- Cancer Medicine
- Published
- 2024-11-01
- DOI
- https://doi.org/10.1002/cam4.70029
- Citations
- 5
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 2.09
Funders
- Sanofi
- Astellas Pharma